Pfizer predicts Covid-19 vaccines will remain 'multi-billion-dollar revenue generators'

Company plans to quadruple the price of the vaccine in the US once the US government stops buying doses and shifts to a private market

Third-quarter sales of the Covid-19 vaccine came in at $4.4bn, blowing past estimates of $2.6bn.

Pfizer has raised its forecast for annual sales of its Covid-19 vaccine by $2bn to $34bn on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations.

The US drugmaker's shares rose over 2.5% at one stage in the session as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine.